Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC
Vidutolimod 与 Atezolizumab 联合治疗或不联合放射治疗,用于治疗程序性细胞死亡蛋白 1 或程序性死亡配体 1 阻断耐药的晚期 NSCLC 患者
期刊:JTO Clinical and Research Reports
影响因子:3
doi:10.1016/j.jtocrr.2022.100423
Marcelo V Negrao, Vassiliki A Papadimitrakopoulou, Andrew C Price, Alda L Tam, Muhammad Furqan, Sandeep T Laroia, Erminia Massarelli, Jose Pacheco, John V Heymach, Anne S Tsao, Gary V Walker, Lalit Vora, David Mauro, Heather Kelley, James E Wooldridge, Arthur M Krieg, Jiaxin Niu